A carregar...
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
Chimeric antigen receptor (CAR)‐T cell therapy is now approved in the United States and Europe as a standard treatment for relapsed/refractory B‐cell malignancies. It has also been approved recently by the Therapeutic Goods Administration in Australia and may soon be publicly reimbursed. This advanc...
Na minha lista:
| Publicado no: | Clin Transl Immunology |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6526894/ https://ncbi.nlm.nih.gov/pubmed/31139410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1050 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|